

December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2008-008748-26/ Novartis Protocol ID CQAB149B2312

A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 µg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease Novartis Pharmaceuticals (COPD)

Trial CQAB149B2312 was cancelled with no patient enrollment and as such, no results will be reported.